|Bid||3.9700 x 1800|
|Ask||4.2300 x 800|
|Day's Range||3.9000 - 4.0100|
|52 Week Range||2.5100 - 4.1900|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||68.45|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||3.40|
Zacks.com featured highlights include: CNX Midstream Partners LP, Akoustis Technologies, CRH Medical, Mesoblast and Photronics
Picking breakout stocks is one of the most-favored methods for those utilizing an active investing approach since this strategy offers the promise of superlative returns.
CRH Medical Corporation (TSX: CRH) (NYSE MKT: CRHM) ("CRH" or the "Company"), today announced the appointment of Tom Sanders as Vice President of Commercial Development.
With the first-quarter round of 13F filings behind us it is time to take a look at the stocks in which some of the best money managers in the world preferred to invest or sell heading into the second quarter. One of these stocks was CRH Medical Corporation (NYSE:CRHM). Hedge fund interest in CRH Medical […]
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Zacks.com featured highlights include: The Bancorp, CRH Medical, Intellicheck, Luna Innovations and Lloyds Banking
Today, we'll introduce the concept of the P/E ratio for those who are learning about investing. To keep it practical...
CRH Medical (CRHM) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
VANCOUVER , Nov. 19, 2019 /PRNewswire/ - CRH Medical Corporation (the "Company" ) (TSX: CRH) (NYSE MKT: CRHM), announces that it has exercised its option, effective November 1, 2019 , completing ...
While some investors are already well versed in financial metrics (hat tip), this article is for those who would like...
VANCOUVER , Nov. 6, 2019 /CNW/ - CRH Medical Corporation (the "Company") (CRH.TO) (NYSE American: CRHM), announces that it has received approval from the Toronto Stock Exchange ("TSX") of its Notice of Intention to renew its existing Normal Course Issuer Bid (the "Bid"). Pursuant to the Bid, the Company may purchase for cancellation up to 6,974,495 of its common shares ("Common Shares"), or approximately 9.8% of the Common Shares outstanding as of the date of this announcement (representing 10% of the public float).
VANCOUVER , Oct. 24, 2019 /PRNewswire/ - CRH Medical Corporation (TSX: CRH) (NYSE MKT: CRHM) (the "Company"), plans to release its results for the quarter ended September 30, 2019 , on Thursday, ...